National Bank of Canada
ACRS icon

National Bank of Canada’s Aclaris Therapeutics ACRS Stock Holding History

National Bank of Canada’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$540 Buy
+102
New +$455 ﹤0.01% 2845

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

National Bank of Canada's ACRS Position: Q2 2026 in Review

National Bank of Canada opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 102 shares worth $540. The stake represents ﹤0.01% of the portfolio and ranks #2845 among its holdings.

149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • National Bank of Canada held 102 shares of Aclaris Therapeutics worth $540 as of Q2 2026.
  • Aclaris Therapeutics was a new National Bank of Canada position in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2845 holding.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.